Live Breaking News & Updates on Weiguo su

Stay informed with the latest breaking news from Weiguo su on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Weiguo su and stay connected to the pulse of your community

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China , Macau-special-administrative-region , Macau-general- , Macau , Shanghai , Hong-kong , Hainan , United-states , Japan , Japanese , American , Eli-lilly

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 -- HUTCHMED Limited today announced that, Inmagene Biopharmaceuticals has exercised options to license two drug candidates...

China , Shanghai , Japan , Hong-kong , Weiguo-su , Crossley-daphne , Ben-atwell , Atholl-tweedie-freddy , Zhou-yi , Nasdaq , Exchange-commission , Linkedin

HUTCHMED Announces that Inmagene Exercises Option to

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...

Japan , Hong-kong , China , Shanghai , Zhou-yi , Ben-atwell , Atholl-tweedie-freddy , Crossley-daphne , Weiguo-su , Nasdaq , Exchange-commission , China-limited

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Japan , Shanghai , China , Hong-kong , Atholl-tweedie-freddy , Ben-atwell , Weiguo-su , Zhou-yi , Crossley-daphne , China-limited , Nasdaq , Stock-exchange-of-hong-kong

Hutchmed says Inmagene exercises option to licence drug candidates

Hutchmed Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

The immunotherapy developer, which was founded...

Hong-kong , Weiguo-su , Alliance-news , Hutchmed-china-ltd-on , Alliance-news-ltd , Inmagene-biopharmaceuticals-ltd , Sabrina-penty , All-rights , Markets ,

HUTCHMED Announces That Inmagene Exercises Option To License Two Drug Candidates As Part Of Strategic Partnership

HUTCHMED Announces That Inmagene Exercises Option To License Two Drug Candidates As Part Of Strategic Partnership
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

China , Shanghai , Weiguo-su , Linkedin , China-limited , Nasdaq , Inmagene-biopharmaceuticals , Chief-executive-officer , Chief-scientific-officer ,

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 —— NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — ...

China , Germany , Spain , Japan , United-kingdom , Hong-kong , France , Italy , Weiguo-su , Stock-exchange-of-hong-kong , Exchange-commission , Practice-research-database

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China , Germany , Spain , France , Brunswick , Niedersachsen , Shanghai , Japan , Italy , United-kingdom , Hong-kong , Zhou-yi

Hutchmed Sovleplenib accepted for review by China drug bureau

Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug...

China , Weiguo-su , Hugh-cameron , Hutchmed-ltd-on , Alliance-news , China-national-medical-products-administration , Alliance-news-ltd , Hong-kong-based , China-national-medical-products , Executive-officer , All-rights , Markets

Hutchmed's hope for adults with primary immune thrombocytopenia

Commercial-stage biopharma company, Hutchmed, has good news for adults with primary immune thrombocytopenia (ITP).

China , Weiguo-su , China-national-medical-products-administration , Lancet-haematology , Breakthrough-therapy , Clinical-development , Rug-delivery , Ngredients , Arkets-amp-regulations , Atient-centricity , Pis-active-pharmaceutical-ingredients- , Egulations